XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Changes in Redeemable Common Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Total
Series A Common Stock
Series B Common Stock
Conversion of Redeemable Common Stock
Conversion of Common Stock Upon Initial Public Offering
Common Stock
Series A Common Stock
Common Stock
Series B Common Stock
Common Stock
Conversion of Redeemable Common Stock
Series B Common Stock
Common Stock
Conversion of Common Stock Upon Initial Public Offering
Series A Common Stock
Common Stock
Conversion of Common Stock Upon Initial Public Offering
Series B Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Conversion of Redeemable Common Stock
Accumulated Deficit
Accumulated Deficit
Conversion of Redeemable Common Stock
Beginning balance (in shares) at Dec. 31, 2021 64,046,223                          
Beginning balance at Dec. 31, 2021 $ 2,566,332,000                          
Redeemable Common Stock                            
Reclassification of redeemable common stock to Series B common stock $ (1,030,207,000)                          
Ending balance (in shares) at Sep. 30, 2022 64,046,223                          
Ending balance at Sep. 30, 2022 $ 1,536,125,000                          
Beginning balance (in shares) at Dec. 31, 2021           0 161,756,287              
Beginning balance at Dec. 31, 2021 (2,236,064,000)         $ 0 $ 162,000       $ 0   $ (2,236,226,000)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Accretion of redeemable common stock to redemption value 1,030,207,000                   1,030,207,000      
Issuance of common stock upon exercise of common stock options (in shares)             1,269,344              
Issuance of common stock upon exercise of common stock options 1,190,000           $ 1,000       1,189,000      
Issuance of common stock, net of issuance costs (in shares)             2,951,846              
Issuance of common stock, net of issuance costs 69,120,000           $ 3,000       69,117,000      
Issuance of common stock upon exercise of collaboration agreement warrants (in shares)             3,935,793              
Issuance of common stock upon exercise of collaboration agreement warrants 40,000           $ 4,000       36,000      
Vested warrants related to collaboration agreement 92,570,000                   92,570,000      
Stock-based compensation expense 6,245,000                   6,245,000      
Issuance of Investment Option, net of issuance costs 30,438,000                   30,438,000      
Vesting of restricted stock common stock (in shares)             26,795              
Vesting of restricted common stock 75,000                   75,000      
Vesting of restricted stock units (in shares)             33,333              
Vesting of restricted stock units 0                          
Net loss (48,438,000)                       (48,438,000)  
Ending balance (in shares) at Sep. 30, 2022           0 169,973,398              
Ending balance at Sep. 30, 2022 $ (1,054,617,000)         $ 0 $ 170,000       1,229,877,000   (2,284,664,000)  
Beginning balance (in shares) at Jun. 30, 2022 64,046,223                          
Beginning balance at Jun. 30, 2022 $ 1,536,125,000                          
Ending balance (in shares) at Sep. 30, 2022 64,046,223                          
Ending balance at Sep. 30, 2022 $ 1,536,125,000                          
Beginning balance (in shares) at Jun. 30, 2022           0 163,007,686              
Beginning balance at Jun. 30, 2022 (1,223,504,000)         $ 0 $ 163,000       1,037,124,000   (2,260,791,000)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Issuance of common stock upon exercise of common stock options (in shares)             69,141              
Issuance of common stock upon exercise of common stock options 47,000           $ 1,000       46,000      
Issuance of common stock, net of issuance costs (in shares)             2,951,846              
Issuance of common stock, net of issuance costs 69,120,000           $ 3,000       69,117,000      
Issuance of common stock upon exercise of collaboration agreement warrants (in shares)             3,935,793              
Issuance of common stock upon exercise of collaboration agreement warrants 39,000           $ 3,000       36,000      
Vested warrants related to collaboration agreement 92,570,000                   92,570,000      
Stock-based compensation expense 522,000                   522,000      
Issuance of Investment Option, net of issuance costs 30,438,000                   30,438,000      
Vesting of restricted stock common stock (in shares)             8,932              
Vesting of restricted common stock 24,000                   24,000      
Net loss (23,873,000)                       (23,873,000)  
Ending balance (in shares) at Sep. 30, 2022           0 169,973,398              
Ending balance at Sep. 30, 2022 $ (1,054,617,000)         $ 0 $ 170,000       1,229,877,000   (2,284,664,000)  
Beginning balance (in shares) at Dec. 31, 2022 64,046,223                          
Beginning balance at Dec. 31, 2022 $ 1,531,853,000                          
Redeemable Common Stock                            
Accretion of redeemable common stock to redemption value $ 399,685,000                          
Reclassification of redeemable common stock to Series B common stock (in shares) (64,046,223)                          
Reclassification of redeemable common stock to Series B common stock $ (1,931,538,000)                          
Ending balance (in shares) at Sep. 30, 2023 0                          
Ending balance at Sep. 30, 2023 $ 0                          
Beginning balance (in shares) at Dec. 31, 2022   0 170,855,313     0 170,855,313              
Beginning balance at Dec. 31, 2022 (1,036,183,000)         $ 0 $ 171,000       1,249,065,000   (2,285,419,000)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Accretion of redeemable common stock to redemption value (399,685,000)                   (399,685,000)      
Issuance of common stock upon exercise of common stock options (in shares)             2,309,707              
Issuance of common stock upon exercise of common stock options 3,933,000           $ 3,000       3,930,000      
Issuance of common stock, net of issuance costs (in shares)           11,507,693                
Issuance of common stock, net of issuance costs 319,953,000         $ 12,000         319,941,000      
Issuance of common stock upon vesting of restricted stock units (in shares)             6,162,692              
Issuance of common stock upon vesting of restricted stock units 0           $ 6,000       (6,000)      
Issuance of common stock upon exercise of collaboration agreement warrants (in shares)             5,706,904              
Issuance of common stock upon exercise of collaboration agreement warrants 57,000           $ 5,000       52,000      
Vested warrants related to collaboration agreement 134,225,000                   134,225,000      
Stock-based compensation expense 303,534,000                   303,534,000      
Vesting of restricted stock common stock (in shares)             26,795              
Vesting of restricted common stock 75,000                   75,000      
Vesting of restricted stock units (in shares)             33,333              
Shares withheld for tax withholding upon vesting of restricted stock units (in shares)     (2,350,702)                      
Shares withheld for tax withholding upon vesting of restricted stock units (70,165,000)           $ (2,000)       (70,163,000)      
Conversion of common stock (in shares)               64,046,223 21,233,074 (21,233,074)        
Conversion of common stock       $ 1,931,538,000 $ 0     $ 64,000 $ 21,000 $ (21,000)   $ 136,865,000   $ 1,794,609,000
Net loss (281,938,000)                       (281,938,000)  
Ending balance (in shares) at Sep. 30, 2023   32,740,767 225,557,191     32,740,767 225,557,191              
Ending balance at Sep. 30, 2023 $ 905,344,000         $ 33,000 $ 226,000       1,677,833,000   (772,748,000)  
Beginning balance (in shares) at Jun. 30, 2023 64,046,223                          
Beginning balance at Jun. 30, 2023 $ 1,625,825,000                          
Redeemable Common Stock                            
Accretion of redeemable common stock to redemption value $ 305,713,000                          
Reclassification of redeemable common stock to Series B common stock (in shares) (64,046,223)                          
Reclassification of redeemable common stock to Series B common stock $ (1,931,538,000)                          
Ending balance (in shares) at Sep. 30, 2023 0                          
Ending balance at Sep. 30, 2023 $ 0                          
Beginning balance (in shares) at Jun. 30, 2023           0 173,222,733              
Beginning balance at Jun. 30, 2023 (1,082,474,000)         $ 0 $ 173,000       1,187,606,000   (2,270,253,000)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Accretion of redeemable common stock to redemption value (305,713,000)                   (305,713,000)      
Issuance of common stock upon exercise of common stock options (in shares)             1,174,225              
Issuance of common stock upon exercise of common stock options 1,591,000           $ 1,000       1,590,000      
Issuance of common stock, net of issuance costs (in shares)           11,507,693                
Issuance of common stock, net of issuance costs 319,953,000         $ 12,000         319,941,000      
Issuance of common stock upon vesting of restricted stock units (in shares)             6,162,692              
Issuance of common stock upon vesting of restricted stock units 0           $ 6,000       (6,000)      
Issuance of common stock upon exercise of collaboration agreement warrants (in shares)             4,526,162              
Issuance of common stock upon exercise of collaboration agreement warrants 46,000           $ 5,000       41,000      
Vested warrants related to collaboration agreement 106,455,000                   106,455,000      
Stock-based compensation expense 301,192,000                   301,192,000      
Vesting of restricted stock common stock (in shares)             8,932              
Vesting of restricted common stock 25,000                   25,000      
Shares withheld for tax withholding upon vesting of restricted stock units (in shares)     (2,350,702)                      
Shares withheld for tax withholding upon vesting of restricted stock units (70,165,000)           $ (2,000)       (70,163,000)      
Conversion of common stock (in shares)               64,046,223 21,233,074 (21,233,074)        
Conversion of common stock       $ 1,931,538,000 $ 0     $ 64,000 $ 21,000 $ (21,000)   $ 136,865,000   $ 1,794,609,000
Net loss (297,104,000)                       (297,104,000)  
Ending balance (in shares) at Sep. 30, 2023   32,740,767 225,557,191     32,740,767 225,557,191              
Ending balance at Sep. 30, 2023 $ 905,344,000         $ 33,000 $ 226,000       $ 1,677,833,000   $ (772,748,000)